RxDoctor Payments Data

Sanjaykumar Patel, MD

Interventional Cardiology · The Woodlands, TXNPI 1306030150

Payments from drug & device makers

$4,888in general payments, 2019–2025

Across 204 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$471
  • Abbott$468
  • Abiomed$301
  • Johnson & Johnson$298
  • Kestra Medical Technology Services, Inc.$269
  • Medtronic$222
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$4,888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,888 in reported general payments places this provider in the 25th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$580,668
Medicare patients
707
Services billed
4,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban452$476,502
EntrestoSacubitril/Valsartan98$124,341
XareltoRivaroxaban111$113,937
Repatha SureclickEvolocumab38$42,217
BrilintaTicagrelor41$28,220
FarxigaDapagliflozin Propanediol22$14,482
Nebivolol Hcl216$11,429
Ranolazine ErRanolazine60$8,418
ClopidogrelClopidogrel Bisulfate592$7,303
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,257
Rosuvastatin Calcium522$6,102
Clonidine27$4,832
Bisoprolol Fumarate164$4,060
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide131$3,595
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide98$3,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$476,502452 claims
NovartisEntresto$155$124,34198 claims
Johnson & JohnsonXarelto$298$113,937111 claims
AstraZenecaBrilinta, Farxiga$146$42,70263 claims
GSKTrelegy Ellipta$25$7,25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →